Objective: The study aimed to observe the clinical efficacy and safety of Shenling Baizhu powder on patients with hyperlipidemia. Method: In this study

136 patients with hyperlipidemia were randomly divided into the treatment group(referred to as Shenling Baizhu powder treatment) and the control group(referred to as the western medicine simvastatin treatment)with 68 patients in each group. Each group was treated for 8 weeks

and the clinical effect

lipid changes

blood rheology changes and side-effects before and after treatment were observed. Result: ① The total effective rate of the treatment group was 86.8%

while it was 83.8% in the control group. With no significant difference. ② The total effective rate of traditional Chinese medicine(TCM)syndrome in treatment group was 89.7%

while it was 54.4% in control group

with significant difference between two groups (P<0.01). ③There were significant change in the total cholesterol(TC)

triglyceride(TG)

high density lipoprotein cholesterol(HDL-C) and low density lipoprotein cholesterol(LDL-C)between the two groups after treatment (P<0.01

P<0.05). The effects of reducing TG in the treatment group[the treatment group was (1.86± 0.51) mol·L-1

and the control group was(2.54±0.69) mmol·L-1]and elevating HDL-C[The treatment group was (1.74±0.52)

and the control group was (1.19±0.40) mmol·L-1]were better than those in control group after treatment (P<0.05).④ In the two groups

the whole blood high shear viscosity

whole blood low shear viscosity

plasma viscosity and erythrocyte deposited were all had significantly lower than before treatment (P<0.05)

but with no significant difference between the two groups.⑤No side-effects were observed in treatment group. Conclusion: The total effective rate of Shenling Baizhu powder is equivalent to simvastatin in treating hyperlipidemia

but better than control group in reducing TG and elevating HDL-C is

which can alleviate the syndromes of patients

improve the blood rheology

with no side-effects.